Sponsor:
Rigel Pharmaceuticals
Code:
NCT07486713
Conditions
AML (Acute Myeloid Leukemia)
Glioma
Cholangiocarcinoma
Solid Tumor Malignancies
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Olutasidenib
CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-12. This information was provided to ClinicalTrials.gov by Rigel Pharmaceuticals on 2026-03-20.